Skip to content

Medical emergency? What to do

Vasogen heart therapy cuts risk in 70 pct of patients

3-RXPublished September 6, 20063 min read

Key points

  • A heart treatment from Canadian biotech firm Vasogen Inc., which failed a key clinical trial hurdle in June, still helped more than 70 percent of patients, researchers said on Sunday.
  • If all goes well Celacade could go on sale in Europe in mid-2007.
  • But a review of the full data set released on Sunday showed there was a 21 percent reduction in risk in a 1,746 patient sub-group who had not progressed to the more advanced stages of heart failure.
  • Elsley said he was in advanced discussions with a number of potential partners who could market Celacade, initially in Europe, where the treatment already has a CE mark, or regulatory approval.

A heart treatment from Canadian biotech firm Vasogen Inc., which failed a key clinical trial hurdle in June, still helped more than 70 percent of patients, researchers said on Sunday.

Vasogen Chief Executive David Elsley told Reuters he was confident the detailed analysis presented at the World Congress of Cardiology meant its Celacade device-based therapy now had a promising commercial future.

If all goes well Celacade could go on sale in Europe in mid-2007. Elseley - who previously said he expected to have to do another study to win U.S. approval - added the firm would now also discuss the results with U.S. and Canadian regulators.

Shares in Vasogen fell more than 70 percent in June on news Celacade had not reached its primary goal of significantly reducing the overall risk of death and cardiovascular hospitalisation in a 2,408-patient Phase III clinical trial.

But a review of the full data set released on Sunday showed there was a 21 percent reduction in risk in a 1,746 patient sub-group who had not progressed to the more advanced stages of heart failure.

Principal investigator Dr Guillermo Torre-Amione of the DeBakey Heart Center of The Methodist Hospital in Houston, Texas, said the results provided "compelling evidence" that Celacade could help an important group of heart failure patients.

SEEKING A PARTNER

Elsley said he was in advanced discussions with a number of potential partners who could market Celacade, initially in Europe, where the treatment already has a CE mark, or regulatory approval.

"Our therapy has been shown to be effective in patients that have not progressed to late-stage disease, at which point they become refractory to intervention," he said in an interview. "We are looking at a very broad population."

The latest results showed Celacade helped not only patients with class II chronic heart failure, as assessed by the New York Heart Association, but also sicker class III and IV patients, provided they had not suffered a previous heart attack.

Confidence in the company - which has only enough cash to fund operations for another year - was dealt a serious blow by the initial setback to hopes for its leading product.

But Elsley said he believed Vasogen's fortunes had turned, adding that the group hoped to receive a cash injection under a future Celacade marketing deal.

"We certainly expect the market will be impressed by this data," he said.

Vasogen's Celacade technology involves taking a small sample of blood from patients with heart failure and treating it to target the chronic inflammation associated with cardiovascular disease. It is then re-administered to the patient intramuscularly.

Heart failure occurs when the heart is unable to maintain adequate circulation of blood in the body's tissues, resulting in shortness of breath, excessive tiredness and fluid buildup.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underHeart

Keep reading

Heart

Early sexual abuse increases heart risks

Women who were repeatedly sexually abused as girls have a 62 percent higher risk of heart problems later in life compared with women who were not abused, U.S. researchers said on Sunday. The findings, presented at…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.